Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ALX Oncology Holdings ( (ALXO) ) has shared an update.
Effective January 21, 2026, ALX Oncology Holdings Inc.’s board amended its 2025 Inducement Equity Incentive Plan to increase the total number of shares of common stock reserved for issuance under the plan to 2,800,000, including an additional 1,300,000 shares. The expanded inducement plan, adopted without stockholder approval in line with Nasdaq listing rules, continues to mirror the company’s main equity incentive plan in structure and change‑of‑control treatment, and is designed to issue equity awards solely to new hires or rehires as a material inducement to employment, underscoring the company’s intention to use equity compensation more extensively in talent recruitment and retention.
The most recent analyst rating on (ALXO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on ALX Oncology Holdings stock, see the ALXO Stock Forecast page.
Spark’s Take on ALXO Stock
According to Spark, TipRanks’ AI Analyst, ALXO is a Neutral.
The score is held down primarily by weak financial performance (no revenue, sizable losses, and significant cash burn with a shrinking equity cushion) and soft technicals (below key moving averages with negative MACD). These are partly offset by a constructive earnings-call backdrop, including strong ASPEN-06 efficacy signals and a stated cash runway into Q1 2027.
To see Spark’s full report on ALXO stock, click here.
More about ALX Oncology Holdings
Average Trading Volume: 268,231
Technical Sentiment Signal: Sell
Current Market Cap: $63.44M
See more data about ALXO stock on TipRanks’ Stock Analysis page.